LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of United Therapeutics Corporation (“United Therapeutics” or the “Company”) (Nasdaq: UTHR).
If you purchased or otherwise acquired United Therapeutics shares, and would like more information about the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you.
The investigation focuses on whether United Therapeutics and certain of its officers and/or directors violated federal securities laws. On July 27, 2017, the Company revealed that it recorded a $210 million accrual relating to a potential settlement in connection with a Department of Justice investigation into the Company’s possible violations of the Federal Anti-Kickback Statute and the Federal False Claims Act. Following this news, United Therapeutics’ stock price dropped.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at firstname.lastname@example.org.
Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.